Affinia Therapeutics
- Biotech or pharma, therapeutic R&D
Affinia discovers and develops novel AAV capsids with specific tissue tropisms to enable targeted delivery and expand the reach of gene therapies to more prevalent patient populations. We use cutting-edge scientific tools to methodically engineer novel AAV capsids, enabling them to better target desired tissues while avoiding sites of toxicity. Our goal is genetic medicines that can be given as a one-time dose to effectively and safely correct defective genes in the body – the underlying root cause of many diseases. Our initial programs are focused on genetic cardiomyopathies and diseases of the CNS, where the patient need is high and the limitation for gene therapy is one of targeted delivery. Our platform gives us an advantage to develop first-in-class or best-in-class product candidates for these diseases. Our lead product, AFTX-201, is being advanced into Ph1/2 trials for BAG-3 Dilated Cardiomyopathy with expected readout in 2026.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}